Published in Cancer Res on May 01, 1993
Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J Cell Biol (1998) 2.00
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J (1999) 0.96
Identification of one- and two-chain forms of trypsinogen 1 produced by a human gastric adenocarcinoma cell line. Biochem J (1994) 0.91
Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells. Gut (2007) 0.86
Laminin-111-derived peptides and cancer. Cell Adh Migr (2012) 0.82
The laminin alpha-1 chain derived peptide, AG73, increases fibronectin levels in breast and melanoma cancer cells. Clin Exp Metastasis (2008) 0.80
The preparation of simulated water samples for the purpose of bacteriological quality control. J Hyg (Lond) (1976) 2.71
Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem (1973) 2.45
Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. J Biol Chem (1981) 2.15
Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A (1999) 1.95
Do new caledonian crows solve physical problems through causal reasoning? Proc Biol Sci (2009) 1.91
Hepatic receptor that specifically binds oligosaccharides containing fucosyl alpha1 leads to 3 N-acetylglucosamine linkages. Proc Natl Acad Sci U S A (1978) 1.87
Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J Immunol (1980) 1.85
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A (2001) 1.83
Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. N Engl J Med (1980) 1.81
Model of alpha 2-macroglobulin structure and function. Proc Natl Acad Sci U S A (1985) 1.79
Career characteristics of graduates of a Medical Scientist Training Program, 1970-1990. Acad Med (1996) 1.58
Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. J Clin Invest (1979) 1.55
Animal behaviour: Laterality in tool manufacture by crows. Nature (2001) 1.54
Oxidative dissociation of human alpha 2-macroglobulin tetramers into dysfunctional dimers. J Biol Chem (1994) 1.53
Physical properties of human alpha 2-macroglobulin following reaction with methylamine and trypsin. Biochim Biophys Acta (1982) 1.49
Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem (1977) 1.47
The subunit structure of normal and hemophilic factor VIII. J Clin Invest (1973) 1.46
Selective diminution of the binding of mannose by murine macrophages in the late stages of activation. J Biol Chem (1982) 1.45
The effect of plasmin on the subunit structure of human fibrinogen. J Biol Chem (1972) 1.44
Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J Cell Biochem (1985) 1.42
The shape and tempo of language evolution. Proc Biol Sci (2010) 1.36
alpha 2-Macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest (1994) 1.33
Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages. Science (1982) 1.31
The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem (1971) 1.30
The effect of inositol hexaphosphate on the kinetics of CO and O 2 binding by human hemoglobin. J Biol Chem (1971) 1.30
Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol (2001) 1.29
Analysis of inter-alpha-trypsin inhibitor and a novel trypsin inhibitor, pre-alpha-trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. J Biol Chem (1989) 1.29
Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry (1989) 1.28
The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest (1971) 1.22
Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. J Leukoc Biol (1988) 1.20
Effects of bacterial lipopolysaccharide on the hydrolysis of phosphatidylinositol-4,5-bisphosphate in murine peritoneal macrophages. J Immunol (1987) 1.19
Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer (1996) 1.19
A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal Biochem (1983) 1.19
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. J Neuropathol Exp Neurol (1982) 1.18
Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-alpha-inhibitor. J Biol Chem (1991) 1.16
Seabird and louse coevolution: complex histories revealed by 12S rRNA sequences and reconciliation analyses. Syst Biol (2000) 1.12
Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. J Histochem Cytochem (1982) 1.10
Precipitation of fibrinogen, fibrinogen degradation products and fibrin monomer by histone H3. Thromb Res (1985) 1.09
Ligand binding, conformational change and plasma elimination of human, mouse and rat alpha-macroglobulin proteinase inhibitors. Biochem J (1983) 1.08
The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. J Biol Chem (2000) 1.08
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer (1994) 1.08
Binding of alpha 2-macroglobulin to hepatocytes: mechanism of in vivo clearance. Biochem Biophys Res Commun (1985) 1.07
The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem (1993) 1.05
Catabolism of human tissue plasminogen activator in mice. Blood (1985) 1.05
Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-alpha-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem (1993) 1.05
Crystal structure of a complex between Pseudomonas aeruginosa alkaline protease and its cognate inhibitor: inhibition by a zinc-NH2 coordinative bond. J Biol Chem (2001) 1.05
Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. Mol Psychiatry (2007) 1.04
Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide. J Biol Chem (1989) 1.04
The effect of plasmin on the subunit structure of human fibrin. J Biol Chem (1973) 1.03
The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem (1982) 1.03
The effect of 2,3-diphosphoglycerate on the tetramer-dimer equilibrium of liganded hemoglobin. J Biol Chem (1974) 1.01
Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin. J Clin Invest (1982) 1.01
Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci (1989) 1.00
Selective upregulated expression of the alpha2-macroglobulin signaling receptor in highly metastatic 1-LN prostate carcinoma cells. Arch Biochem Biophys (2000) 1.00
Receptor-mediated antigen delivery into macrophages. Complexing antigen to alpha 2-macroglobulin enhances presentation to T cells. J Immunol (1993) 0.99
Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the carboxyl-terminal domain of GRP78. Apoptosis (2010) 0.98
In vivo catabolism of alpha 1-proteinase inhibitor-trypsin, antithrombin III-thrombin and alpha 2-macroglobulin-methylamine. Biochim Biophys Acta (1982) 0.98
Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages. J Leukoc Biol (2001) 0.97
Structure of inter-alpha-inhibitor (inter-alpha-trypsin inhibitor) and pre-alpha-inhibitor: current state and proposition of a new terminology. Biol Chem Hoppe Seyler (1990) 0.97
The relationship between low density lipoprotein-related protein/alpha 2-macroglobulin (alpha 2M) receptors and the newly described alpha 2M signaling receptor. J Biol Chem (1994) 0.97
Mechanism of insulin incorporation into alpha 2-macroglobulin: implications for the study of peptide and growth factor binding. Biochemistry (1991) 0.96
Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med (1986) 0.96
Characterization of functional human alpha 2-macroglobulin half-molecules isolated by limited reduction with dithiothreitol. Biochemistry (1983) 0.96
Kinetics and mechanism of bilirubin binding to human serum albumin. J Biol Chem (1978) 0.96
Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. Arch Biochem Biophys (1991) 0.95
A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem (1995) 0.95
The potential role of alpha 2-macroglobulin in the control of cysteine proteinases (gingipains) from Porphyromonas gingivalis. J Periodontal Res (1997) 0.95
Functional inactivation and structural disruption of human alpha 2-macroglobulin by neutrophils and eosinophils. J Biol Chem (1989) 0.95
Conformation and protease binding activity of binary and ternary human alpha 2-macroglobulin-protease complexes. J Biol Chem (1983) 0.94
Chemical and structural modifications of alpha 2-macroglobulin: effects on receptor binding and endocytosis studied in an in vivo model. Ann N Y Acad Sci (1983) 0.94
Alpha-macroglobulin from Limulus polyphemus exhibits proteinase inhibitory activity and participates in a hemolytic system. Biochemistry (1990) 0.94
Oxidized alpha2-macroglobulin (alpha2M) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. J Immunol (1998) 0.94
Alkaline proteinase inhibitor of Pseudomonas aeruginosa. Interaction of native and N-terminally truncated inhibitor proteins with Pseudomonas metalloproteinases. J Biol Chem (2000) 0.93
Localization of factor VIII/von Willebrand factor and glial fibrillary acidic protein in the hemangioblastoma: implications for stromal cell histogenesis. Acta Neuropathol (1982) 0.93
Proteinase binding and inhibition by the monomeric alpha-macroglobulin rat alpha 1-inhibitor-3. J Biol Chem (1989) 0.92
Changes in the binding of "fast"-form alpha 2-macroglobulin to 3T3-L1 cells after differentiation to adipocytes. Biochemistry (1984) 0.92
Quaternary structure of partially liganded intermediates of sheep carbon monoxide hemoglobin at alkaline pH. J Biol Chem (1975) 0.92
Regulation of plasminogen activation by components of the extracellular matrix. Biochemistry (1990) 0.92
Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues. J Biol Chem (1978) 0.92
Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med (1987) 0.92
The binding of fucose-containing glycoproteins by hepatic lectins. Re-examination of the clearance from blood and the binding to membrane receptors and pure lectins. J Biol Chem (1986) 0.92
Evidence for a second alpha 2-macroglobulin receptor. J Biol Chem (1994) 0.92
Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol (2002) 0.92
Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clin Exp Allergy (2003) 0.92
Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochemistry (1989) 0.92
Streptokinase and human fibronectin share a common epitope: implications for regulation of fibrinolysis and rheumatoid arthritis. Biochim Biophys Acta (1993) 0.92
Binding of human plasminogen to basement-membrane (type IV) collagen. Biochem J (1992) 0.91
Inhibition of alkali-induced corneal ulceration and perforation by a thiol peptide. Invest Ophthalmol Vis Sci (1990) 0.91
Alpha 2-macroglobulin 'fast' forms inhibit superoxide production by activated macrophages. Biochim Biophys Acta (1983) 0.91
Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation. Proc Natl Acad Sci U S A (1979) 0.91
Alpha 2-macroglobulin: a sensor for proteolysis. Ann N Y Acad Sci (1994) 0.91
Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. J Clin Invest (1972) 0.91
Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation. Biochem Biophys Res Commun (2010) 0.90
A unique pathway for the plasma elimination of alpha 2-antiplasmin-protease complexes in mice. Thromb Haemost (1982) 0.90
Nonproteolytic incorporation of protein ligands into human alpha 2-macroglobulin: implications for the binding mechanism of alpha 2-macroglobulin. Biochemistry (1998) 0.90
The binding of carbon monoxide to and chains in tetrameric mammalian hemoglobin. J Biol Chem (1971) 0.90
Subunit structure of fragment D from fibrinogen and cross-linked fibrin. J Biol Chem (1973) 0.90
Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of alpha2-macroglobulin to 1-LN prostate cancer cells. Cell Signal (2004) 0.90